Psyence Biomedical Closes Acquisition of Psyence Group's Stake in PsyLabs

Psyence Biomedical Ltd., listed on Nasdaq as PBM, has successfully completed the acquisition of an 11.13% stake in PsyLabs, previously held by Psyence Group. This acquisition cements Psyence Biomedical's strategy of becoming a prominent player in the field of pharmaceutical-grade psychedelic therapies, potentially targeting mental health disorders such as Alcohol Use Disorder (AUD) and other Substance Use Disorders (SUDs). The acquisition was executed through a debt-for-equity swap, resulting in the issuance of 845,394 common shares to Psyence Group at a value of $0.50 per share. This transaction enhances Psyence Biomedical's vertically integrated approach, as PsyLabs is a pivotal partner in producing psychedelic active pharmaceutical ingredients and extracts. The alliance leverages a strategic licensing agreement granting Psyence Biomedical commercial and research rights for these compounds. The parties involved hope to advance significant therapeutic candidates through rigorous clinical trials. Despite certain forward-looking risks, Psyence Biomedical is optimistic about leveraging this acquisition to advance its drug pipeline and expand the commercialization of psychedelic compounds for mental health treatments.